November 22, 2016 - By Darrin Black · 0 Comments
SIGNAL GENETICS (NASDAQ:SGNL) institutional sentiment increased to 1 in Q2 2016. Its up 0.43, from 0.57 in 2016Q1. The ratio improved, as 4 investment professionals started new and increased stock positions, while 7 sold and decreased stakes in SIGNAL GENETICS. The investment professionals in our partner’s database now possess: 715,503 shares, down from 778,231 shares in 2016Q1. Also, the number of investment professionals holding SIGNAL GENETICS in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 3 Increased: 0 New Position: 4.
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The company has a market cap of $6.34 million. The Firm is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. It currently has negative earnings. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature test.
About 17,145 shares traded hands. Signal Genetics Inc (NASDAQ:SGNL) has risen 13.70% since April 20, 2016 and is uptrending. It has outperformed by 9.14% the S&P500.
According to Zacks Investment Research, “Signal Genetics, Inc. is an emerging commercial stage, molecular diagnostic company. It is focused on providing diagnostic services that help physicians in decision making for the care of cancer patients. The Company’s flagship diagnostic service is the Myeloma Prognostic Risk Signature, or MyPRS (TM). Signal Genetics, Inc. is headquartered in New York.”
Perkins Capital Management Inc holds 0.03% of its portfolio in Signal Genetics Inc for 70,550 shares. Bank Of America Corp De owns 18 shares or 0% of their US portfolio. Moreover, Blackrock Fund Advisors has 0% invested in the company for 1,341 shares. The Illinois-based Citadel Advisors Llc has invested 0% in the stock. Creative Planning, a Kansas-based fund reported 13,165 shares.#img1#
Ratings analysis reveals 100% of Signal Genetics’s analysts are positive. Out of 3 Wall Street analysts rating Signal Genetics, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2.75 while the high is $4.0. The stock’s average target of $3.58 is -56.61% below today’s ($8.25) share price. SGNL was included in 3 notes of analysts from September 23, 2015. The company was maintained on Wednesday, September 23 by Chardan Capital Markets. The rating was initiated by Rodman & Renshaw with “Buy” on Friday, January 8. H.C. Wainwright initiated Signal Genetics Inc (NASDAQ:SGNL) rating on Friday, January 8. H.C. Wainwright has “Buy” rating and $4 price target.
Signal Genetics, Inc., incorporated on December 8, 2010, is a commercial stage, molecular genetic diagnostic company. The Firm is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options.
Another recent and important Signal Genetics Inc (NASDAQ:SGNL) news was published by Marketwatch.com which published an article titled: “Virtual Stock Exchange” on June 14, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black